Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06839144 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression

Study acronym: OC-POP-PT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 11, 2025 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Feb 28, 2027 to Aug 31, 2026
    • Study completion date: Apr 30, 2027 to Aug 31, 2026
    • Start date changed from estimate of Feb 28, 2025 to Mar 12, 2025
    • Site details revised at 2 of 2 sites
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.
Trial Details
NCT Number NCT06839144
Lead Sponsor Tel-Aviv Sourasky Medical Center
Collaborators: National Cancer Institute (NCI), The Chaim Sheba Medical Center
Conditions
(from sponsor)		 Ovarian Cancer, Ovarian Cancer Metastatic Recurrent
Related terms Neoplasms, Ovarian Neoplasms
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov